Are glitazones known to be associated with hepatotoxicity?

Glitazones, which are a class of medications used primarily in the management of type 2 diabetes, have been studied for their safety profile, including their impact on liver health. Generally, glitazones are not commonly associated with hepatotoxicity. While there may be instances of hepatic enzyme elevations in certain patients, these occurrences are considered rare and do not suggest a direct, consistent risk of liver damage for the population using glitazones.

The main concern regarding hepatotoxicity typically lies with other classes of diabetes medications rather than glitazones. Therefore, the statement that glitazones are not associated with hepatotoxicity aligns with current understanding, reflecting their relative safety in this aspect. It's important for healthcare providers to monitor liver function in patients taking any medication, but glitazones do not carry a significant risk of causing liver injury compared to other treatments.